Healthcare - Biotechnology - NASDAQ - US
$ 0.5655
-9.14 %
$ 21.6 M
Market Cap
-0.32
P/E
Bolt Biotherapeutics, Inc., a clinical-stage biotechnology company, engages in the development of immuno-oncology agents to target tumor cells for elimination by the immune system. The company is developing BDC-1001, a human epidermal growth factor receptor 2 (HER2), which is in Phase I/II clinical trial for the treatment of patients with HER2-expressing solid tumors, including HER2-low tumors; BDC-2034, a carcinoembryonic antigen program for colorectal, non-small cell lung, pancreatic, and breast cancers; and BDC-3042, a Dectin-2 agonist antibody program developed to repolarize critical cells in the tumor microenvironment by targeting cell-surface receptors on macrophages. It is also developing programmed cell death-ligand 1 program for tumors that are nonresponsive to immune checkpoint blockade.[ Read More ]
The intrinsic value of one BOLT stock under the base case scenario is HIDDEN Compared to the current market price of 0.566 USD, Bolt Biotherapeutics, Inc. is HIDDEN
2. FUNDAMENTAL
ANALYSIS
Price Chart BOLT
FINANCIALS
7.88 M
REVENUE
-76.2 M
OPERATING INCOME
-69.2 M
NET INCOME
-69.5 M
OPERATING CASH FLOW
71 M
INVESTING CASH FLOW
253 K
FINANCING CASH FLOW
1.14 M
REVENUE
-16.4 M
OPERATING INCOME
-15.2 M
NET INCOME
-14 M
OPERATING CASH FLOW
17.1 M
INVESTING CASH FLOW
0
FINANCING CASH FLOW
Balance Sheet Decomposition
Bolt Biotherapeutics, Inc.
| Current Assets | 106 M |
| Cash & Short-Term Investments | 102 M |
| Receivables | 0 |
| Other Current Assets | 3.52 M |
| Non-Current Assets | 54.1 M |
| Long-Term Investments | 26.4 M |
| PP&E | 24.1 M |
| Other Non-Current Assets | 3.59 M |
| Current Liabilities | 20.5 M |
| Accounts Payable | 2.99 M |
| Short-Term Debt | 5.56 M |
| Other Current Liabilities | 11.9 M |
| Non-Current Liabilities | 26.6 M |
| Long-Term Debt | 17.4 M |
| Other Non-Current Liabilities | 9.15 M |
EFFICIENCY
Earnings Waterfall
Bolt Biotherapeutics, Inc.
| Revenue | 7.88 M |
| Cost Of Revenue | 61.5 M |
| Gross Profit | -53.7 M |
| Operating Expenses | 84.1 M |
| Operating Income | -76.2 M |
| Other Expenses | -7 M |
| Net Income | -69.2 M |
RATIOS
-681.39%
GROSS MARGIN
-967.45%
OPERATING MARGIN
-878.58%
NET MARGIN
-61.38%
ROE
-43.31%
ROA
-65.96%
ROIC
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Bolt Biotherapeutics, Inc.
| Net Income | -69.2 M |
| Depreciation & Amortization | 1.85 M |
| Capital Expenditures | -206 K |
| Stock-Based Compensation | 9.22 M |
| Change in Working Capital | -9.86 M |
| Others | -7.99 M |
| Free Cash Flow | -69.7 M |
Wall Street Analysts Price Targets
Bolt Biotherapeutics, Inc.
Wall Street analysts predict an average 1-year price target for BOLT of $1 , with forecasts ranging from a low of $1 to a high of $1 .
BOLT Lowest Price Target
Wall Street Target
1 USD
76.83%
BOLT Average Price Target
Wall Street Target
1 USD
76.83%
BOLT Highest Price Target
Wall Street Target
1 USD
76.83%
4. DIVIDEND ANALYSIS
0.00%
DIVIDEND YIELD
0.09 USD
DIVIDEND PER SHARE
5. COMPETITION
6. Ownership
Insider Ownership
Bolt Biotherapeutics, Inc.
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
259 K USD 2
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
9.08 K USD 1
9-12 MONTHS
| Date | Value | Insider | Amount | Avg Price |
|---|---|---|---|---|
|
11 months ago
Dec 12, 2023
|
Bought 7.12 K USD
|
Quinn William P.
Chief Financial Officer |
+ 7500
|
0.95 USD |
|
11 months ago
Dec 06, 2023
|
Bought 1.96 K USD
|
Quinn William P.
Chief Financial Officer |
+ 2500
|
0.782 USD |
|
1 year ago
Jun 06, 2023
|
Bought 2.16 K USD
|
Quinn William P.
Chief Financial Officer |
+ 1829
|
1.1815 USD |
|
11 months ago
Nov 29, 2023
|
Sell 20.5 K USD
|
ENGLEMAN EDGAR
Director |
- 22674
|
0.906 USD |
|
11 months ago
Nov 30, 2023
|
Sell 92.8 K USD
|
ENGLEMAN EDGAR
Director |
- 108145
|
0.8581 USD |
|
11 months ago
Nov 29, 2023
|
Sell 2.84 K USD
|
ENGLEMAN EDGAR
Director |
- 3131
|
0.906 USD |
|
11 months ago
Nov 30, 2023
|
Sell 12.8 K USD
|
ENGLEMAN EDGAR
Director |
- 14934
|
0.8581 USD |
|
11 months ago
Nov 21, 2023
|
Sell 1.54 K USD
|
ENGLEMAN EDGAR
Director |
- 1707
|
0.9014 USD |
|
11 months ago
Nov 21, 2023
|
Sell 213 USD
|
ENGLEMAN EDGAR
Director |
- 236
|
0.9014 USD |
|
11 months ago
Nov 21, 2023
|
Sell 1.54 K USD
|
Vivo Capital VIII, LLC
10 percent owner |
- 1707
|
0.9 USD |
|
11 months ago
Nov 21, 2023
|
Sell 212 USD
|
Vivo Capital VIII, LLC
10 percent owner |
- 236
|
0.9 USD |
|
11 months ago
Nov 21, 2023
|
Sell 1.31 K USD
|
Vivo Capital VIII, LLC
10 percent owner |
- 1457
|
0.9 USD |
|
1 year ago
Nov 16, 2023
|
Sell 7.23 K USD
|
ENGLEMAN EDGAR
Director |
- 7531
|
0.96 USD |
|
1 year ago
Nov 17, 2023
|
Sell 7.64 K USD
|
ENGLEMAN EDGAR
Director |
- 8211
|
0.93 USD |
|
11 months ago
Nov 20, 2023
|
Sell 25.3 K USD
|
ENGLEMAN EDGAR
Director |
- 27465
|
0.92 USD |
|
1 year ago
Nov 16, 2023
|
Sell 998 USD
|
ENGLEMAN EDGAR
Director |
- 1040
|
0.96 USD |
|
1 year ago
Nov 17, 2023
|
Sell 1.05 K USD
|
ENGLEMAN EDGAR
Director |
- 1134
|
0.93 USD |
|
11 months ago
Nov 20, 2023
|
Sell 3.49 K USD
|
ENGLEMAN EDGAR
Director |
- 3792
|
0.92 USD |
|
1 year ago
Nov 16, 2023
|
Sell 7.23 K USD
|
Vivo Capital VIII, LLC
10 percent owner |
- 7531
|
0.96 USD |
|
1 year ago
Nov 17, 2023
|
Sell 7.64 K USD
|
Vivo Capital VIII, LLC
10 percent owner |
- 8211
|
0.93 USD |
|
11 months ago
Nov 20, 2023
|
Sell 25.3 K USD
|
Vivo Capital VIII, LLC
10 percent owner |
- 27465
|
0.92 USD |
|
1 year ago
Nov 16, 2023
|
Sell 998 USD
|
Vivo Capital VIII, LLC
10 percent owner |
- 1040
|
0.96 USD |
|
1 year ago
Nov 17, 2023
|
Sell 1.05 K USD
|
Vivo Capital VIII, LLC
10 percent owner |
- 1134
|
0.93 USD |
|
11 months ago
Nov 20, 2023
|
Sell 3.49 K USD
|
Vivo Capital VIII, LLC
10 percent owner |
- 3792
|
0.92 USD |
|
1 year ago
Nov 16, 2023
|
Sell 6.17 K USD
|
Vivo Capital VIII, LLC
10 percent owner |
- 6429
|
0.96 USD |
|
1 year ago
Nov 17, 2023
|
Sell 6.52 K USD
|
Vivo Capital VIII, LLC
10 percent owner |
- 7009
|
0.93 USD |
|
11 months ago
Nov 20, 2023
|
Sell 21.6 K USD
|
Vivo Capital VIII, LLC
10 percent owner |
- 23443
|
0.92 USD |
|
2 years ago
Jul 13, 2022
|
Sell 1.6 M USD
|
Novo Holdings A/S
director: |
- 800000
|
2 USD |
|
2 years ago
Dec 06, 2021
|
Bought 1.91 K USD
|
Perez Edith A.
Chief Medical Officer |
+ 411
|
4.64 USD |
|
3 years ago
Jun 04, 2021
|
Bought 15.3 K USD
|
Perez Edith A.
Chief Medical Officer |
+ 917
|
16.65 USD |
|
2 years ago
Dec 08, 2021
|
Bought 23.6 K USD
|
Quinn William P.
Chief Financial Officer |
+ 5000
|
4.715 USD |
|
2 years ago
Dec 06, 2021
|
Bought 162 USD
|
Quinn William P.
Chief Financial Officer |
+ 35
|
4.64 USD |
|
3 years ago
Jun 04, 2021
|
Bought 20.3 K USD
|
Quinn William P.
Chief Financial Officer |
+ 1221
|
16.65 USD |
|
3 years ago
Feb 09, 2021
|
Bought 8 M USD
|
Novo Holdings A/S
10 percent owner |
+ 400000
|
20 USD |
|
3 years ago
Feb 09, 2021
|
Bought 9 M USD
|
Sofinnova Venture Partners X, L.P.
10 percent owner |
+ 450000
|
20 USD |
|
3 years ago
Feb 09, 2021
|
Bought 3.51 M USD
|
Vivo Capital VIII, LLC
10 percent owner |
+ 175733
|
20 USD |
|
3 years ago
Feb 09, 2021
|
Sell 2.88 K USD
|
Vivo Capital VIII, LLC
10 percent owner |
- 144
|
20 USD |
|
3 years ago
Feb 09, 2021
|
Sell 1.24 K USD
|
Vivo Capital VIII, LLC
10 percent owner |
- 62
|
20 USD |
|
3 years ago
Feb 09, 2021
|
Bought 485 K USD
|
Vivo Capital VIII, LLC
10 percent owner |
+ 24267
|
20 USD |
|
3 years ago
Feb 09, 2021
|
Sell 400 USD
|
Vivo Capital VIII, LLC
10 percent owner |
- 20
|
20 USD |
|
3 years ago
Feb 09, 2021
|
Bought 3 M USD
|
Vivo Capital VIII, LLC
10 percent owner |
+ 150000
|
20 USD |
|
3 years ago
Feb 09, 2021
|
Bought 24 K USD
|
LAPORTE KATHLEEN
Director |
+ 1200
|
20 USD |
|
3 years ago
Feb 09, 2021
|
Sell 1.24 K USD
|
SHAH MAHENDRA
Director |
- 62
|
20 USD |
|
3 years ago
Feb 09, 2021
|
Bought 9 M USD
|
HEALY JAMES
Director |
+ 450000
|
20 USD |
|
3 years ago
Feb 09, 2021
|
Bought 24 K USD
|
Khanna Ashish Siri Ram
Director |
+ 1200
|
20 USD |
|
3 years ago
Feb 09, 2021
|
Bought 20 K USD
|
Khanna Ashish Siri Ram
Director |
+ 1000
|
20 USD |
|
3 years ago
Feb 09, 2021
|
Bought 3.51 M USD
|
ENGLEMAN EDGAR
director, 10 percent owner: |
+ 175733
|
20 USD |
|
3 years ago
Feb 09, 2021
|
Sell 2.88 K USD
|
ENGLEMAN EDGAR
director, 10 percent owner: |
- 144
|
20 USD |
|
3 years ago
Feb 09, 2021
|
Bought 485 K USD
|
ENGLEMAN EDGAR
director, 10 percent owner: |
+ 24267
|
20 USD |
|
3 years ago
Feb 09, 2021
|
Sell 400 USD
|
ENGLEMAN EDGAR
director, 10 percent owner: |
- 20
|
20 USD |
|
3 years ago
Feb 09, 2021
|
Bought 24 K USD
|
Quinn William P.
Chief Financial Officer |
+ 1200
|
20 USD |
|
3 years ago
Feb 09, 2021
|
Bought 30 K USD
|
Schatzman Randall C
Chief Executive Officer |
+ 1500
|
20 USD |
7. News
CSE Bulletin: Stock Split - Bolt Metals Corp. (BOLT)
Toronto, Ontario--(Newsfile Corp. - Le 11 novembre/November 2024) - Bolt Metals Corp. has announced a two (2) for one (1) stock split of its issued and outstanding common shares. Each shareholder of record as of the close of business on the record date will receive one (1) additional share for each share held on such date.
newsfilecorp.com
- 5 days ago
Bolt Biotherapeutics Presents Updated Preclinical Data for BDC-4182 and Key Learnings from Phase 1 Dose-Escalation Trial of BDC-1001 at SITC 39th Annual Meeting
BDC-4182 demonstrated compelling anti-tumor activity and an acceptable safety profile in preclinical studies BDC-4182 outperformed cytotoxic claudin 18.2 ADCs in syngeneic model Learnings from BDC-1001 data suggest Boltbody™ ISACs with enhanced immune activation could offer greater efficacy, warranting further testing REDWOOD CITY, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer, today presented updated preclinical data for BDC-4182, a next-generation Boltbody™ ISAC clinical candidate targeting claudin 18.2, and provided key learnings from its Phase 1 dose-escalation trial of BDC-1001 at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC), being held in Houston, Texas from November 6-10, 2024.
globenewswire.com
- 1 week ago
Bolt Biotherapeutics, Inc. May Have Violated Securities Laws And Shareholders Are Urged To Participate In A Case With The Schall Law Firm
LOS ANGELES, CA / ACCESSWIRE / September 6, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Bolt Biotherapeutics, Inc. ("Bolt" or "the Company") (NASDAQ:BOLT) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between February 5, 2021 through May 14, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before September 3, 2024.
accesswire.com
- 2 months ago
The Schall Law Firm Invites Investors To Contribute To A Securities Fraud Lawsuit Against Bolt Biotherapeutics Inc
LOS ANGELES, CA / ACCESSWIRE / September 5, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Bolt Biotherapeutics, Inc. ("Bolt" or "the Company") (NASDAQ:BOLT) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between February 5, 2021 through May 14, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before September 3, 2024.
accesswire.com
- 2 months ago
Bolt Biotherapeutics Announces Changes to its Board of Directors
REDWOOD CITY, Calif., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer, today announced the appointment of Jakob Dupont, M.D., to its Board of Directors. Dr. Dupont brings more than two decades of experience in the field of oncology and immuno-oncology. With the appointment of Dr. Dupont, Executive Partner at Sofinnova Investments, Dr. Jim Healy, M.D., Ph.D., also at Sofinnova, will be stepping down as Lead Independent Director. In addition, Frank D. Lee will be departing the Board and Brian O'Callaghan, CEO of Deep Genomics, will be assuming the role of Chair.
globenewswire.com
- 2 months ago
Bolt Biotherapeutics Inc. May Have Violated Securities Regulations And Stakeholders Are Urged To Reach Out To The Schall Law Firm
LOS ANGELES, CA / ACCESSWIRE / September 4, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Bolt Biotherapeutics, Inc. ("Bolt" or "the Company") (NASDAQ:BOLT) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between February 5, 2021 through May 14, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before September 3, 2024.
accesswire.com
- 2 months ago
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Bolt Biotherapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines - BOLT
NEW YORK , Sept. 3, 2024 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Bolt Biotherapeutics, Inc. ("Bolt" or the "Company") (NASDAQ: BOLT) and certain officers.
prnewswire.com
- 2 months ago
The Schall Law Firm Invites Investors In Bolt Biotherapeutics Inc To Participate In A Securities Fraud Lawsuit
LOS ANGELES, CA / ACCESSWIRE / September 3, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Bolt Biotherapeutics, Inc. ("Bolt" or "the Company") (NASDAQ:BOLT) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between February 5, 2021 through May 14, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before September 3, 2024.
accesswire.com
- 2 months ago
BOLT FINAL DEADLINE: Bronstein, Gewirtz and Grossman, LLC Reminds Bolt Biotherapeutics, Inc. Shareholders of Final Hours to Lead Class Action!
NEW YORK CITY, NY / ACCESSWIRE / September 3, 2024 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Bolt Biotherapeutics, Inc. ("Bolt" or "the Company") (NASDAQ:BOLT) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Bolt securities between February 5, 2021, and May 14, 2024, inclusive (the "Class Period").
accesswire.com
- 2 months ago
BOLT Investors Have the Opportunity to Lead Bolt Biotherapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
LOS ANGELES , Sept. 3, 2024 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Bolt Biotherapeutics, Inc. ("Bolt" or "the Company") (NASDAQ: BOLT) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
prnewswire.com
- 2 months ago
BOLT Deadline: Rosen Law Firm Urges Bolt Biotherapeutics, Inc. (NASDAQ: BOLT) Stockholders with Large Losses to Contact the Firm for Information About Their Rights
NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, reminds investors that a shareholder filed a class action on behalf of all purchasers of securities of Bolt Biotherapeutics, Inc. (NASDAQ: BOLT) between February 5, 2021 and May 14, 2024. Bolt describes itself as a “clinical-stage biopharmaceutical company, [that] engages in the development of immunotherapies for the treatment of cancer.” For more information, submit a form, email attorney Phillip Kim, or give us a ca.
businesswire.com
- 2 months ago
Stakeholders Can Contact The Schall Law Firm About Joining A Case Against Bolt Biotherapeutics Inc. For Securities Law Infractions
LOS ANGELES, CA / ACCESSWIRE / September 2, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Bolt Biotherapeutics, Inc. ("Bolt" or "the Company") (NASDAQ:BOLT) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between February 5, 2021 through May 14, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before September 3, 2024.
accesswire.com
- 2 months ago
8. Profile Summary
Bolt Biotherapeutics, Inc. BOLT
COUNTRY
US
INDUSTRY
Biotechnology
MARKET CAP
$ 21.6 M
Dividend Yield
0.00%
Description
Bolt Biotherapeutics, Inc., a clinical-stage biotechnology company, engages in the development of immuno-oncology agents to target tumor cells for elimination by the immune system. The company is developing BDC-1001, a human epidermal growth factor receptor 2 (HER2), which is in Phase I/II clinical trial for the treatment of patients with HER2-expressing solid tumors, including HER2-low tumors; BDC-2034, a carcinoembryonic antigen program for colorectal, non-small cell lung, pancreatic, and breast cancers; and BDC-3042, a Dectin-2 agonist antibody program developed to repolarize critical cells in the tumor microenvironment by targeting cell-surface receptors on macrophages. It is also developing programmed cell death-ligand 1 program for tumors that are nonresponsive to immune checkpoint blockade. The company was formerly known as Bolt Therapeutics, Inc. and changed its name to Bolt Biotherapeutics, Inc. in July 2015. Bolt Biotherapeutics, Inc. was incorporated in 2015 and is headquartered in Redwood city, California.
Contact
900 Chesapeake Drive, Redwood City, CA, 94063
https://www.boltbio.com
IPO Date
Feb. 5, 2021
Employees
100
Officers
Ms. Sarah Nemec
Vice President of Finance & Principal Accounting Officer
Mr. Grant Yonehiro C.F.A., M.B.A.
Chief Operating Officer
Dr. Michael N. Alonso Ph.D.
Senior Vice President of Research
Mr. Wesley Burwell
Vice President & Head of Human Resources
Mr. William P. Quinn
Chief Executive Officer, Chief Financial Officer, President, Secretary & Director
Dr. Nathan Ihle Ph.D.
Senior Vice President of Pharmaceutical Operations
Dr. Dawn Colburn BCOP, Pharm.D.
Senior Vice President of Clinical Development